Innovations in Molecular Identification of 
*Mycobacterium tuberculosis*

Mohammad Irfan\(^1\) and Dakshina Bisht\(^2\)*

\(^1\)Department of Clinical Laboratory Science, College of Applied Medical Science-Ad Dawadmi, Shaqra University, 17464 Ad Dawadmi, Kingdom of Saudi Arabia.
\(^2\)Department of Microbiology, Santosh Medical College, Santosh University, Ghaziabad - 201 009, Uttar Pradesh, India.

**Abstract**

Tuberculosis (TB) continues to be a significant public health concern on a global scale. Quick and precise identification of *Mycobacterium tuberculosis* (MTB) in symptomatic patients is pivotal for worldwide TB eradication initiatives. As an infectious disorder induced by MTB, it remains a critical threat to public health, particularly in poor countries, due to an inadequate diagnostic research laboratory. There is a need for a persistent incentive to reduce response time for effective diagnosis and control of TB infection, which is a benefit that molecular techniques provide over traditional methods. Although there is a tremendous overall prevalence of TB and a relatively poor probability of case identification worldwide. Common screening techniques have focused on tests that have many fundamental shortcomings. Due to the development of antibiotic-resistant Mycobacterium strains, TB is one of the leading contributors to fatalities. It is now possible to examine TB using molecular detection techniques, which are faster and more cost-effective than previous methods, such as standard culture procedures to test and verify antibiotic resistance in patients with TB. Whole genome sequencing (WGS), faster nucleic acid amplification tests, has made it easier to diagnose and treat TB more quickly. This article addresses the genetic approaches for detecting *Mycobacterium tuberculosis* complex (MTBC) in clinical specimens as well as antibiotic resistance in mycobacterium and discusses the practical limitations of using these methods.

**Keywords:** Nucleic acid amplification test, tuberculosis, *Mycobacterium tuberculosis* complex (MTBC), diagnosis of tuberculosis, Molecular Identification

*Correspondence:* dakshinabisht@gmail.com; +91 9810510852

(Received: December 14, 2021; accepted: February 2, 2022)

Citation: Irfan M, Bisht D. Innovations in Molecular Identification of *Mycobacterium tuberculosis*. *J Pure Appl Microbiol.* 2022;16(1):74-88. [https://doi.org/10.22207/JPAM.16.1.76](https://doi.org/10.22207/JPAM.16.1.76)

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
INTRODUCTION
In 2019, approximately 10 million people across the world were infected with TB. TB affects people of all ages and in all nations. Fortunately, it is possible to treat and prevent TB if caught early.1 India is leading the way with two-thirds of the total cases.1 As reported by WHO in 2020, TB is one of the top ten diseases that cause mortality and the most common cause of death caused by a single infectious pathogen, placing above HIV/AIDS. During the COVID-19 pandemic, there was an increase of approximately 13%, bringing a total of approximately 1.66 (1.3 – 2.1) million TB deaths in 2020.2

Multidrug-resistant TB (MDR-TB) continues to be an issue and a possible threat to public health. In 2019, a net of 206030 people with MDR-TB have been identified and reported worldwide, that is, a 10% increase from 186883 in 2018.1 Globally, the rate of TB infection is falling to 9% between 2015 and 2019.3 This is less than halfway to meeting the End TB Strategy goal of 20% reduction between 2015 and 2020.4 In the year between 2019 and 2020, approximately 60 million individuals were spared via diagnosis and treatment approaches. The United Nations Sustainable Development Goals (SDGs) include a health objective of eradicating TB by 2030.

MDR-TB and Extensively drug-resistant TB (XDR-TB), two forms of drug-resistant, are on the rise in several regions of the globe. The advent of drug-resistant TB highlights the inadequacies of TB eradication efforts and the healthcare system’s failure to prevent resistant forms of illness from emerging. Despite significant advances in TB detection, less than half of all pulmonary TB cases globally were laboratory verified. TB control can be improved by developing and using more sensitive and effective diagnostic technologies that can diagnose MTB quickly and accurately.3 The most widely used method for diagnosing TB is microscopy and it is ineffective in HIV-positive people and children.4 Furthermore, the outcome of this screening does not distinguish between Mycobacterium species.5 Alternatively, Lowenstein-Jensen culture, which is often considered the gold standard in presumptive respiratory infections, looks to be more specific than smear microscopy, however, it is more time-consuming (4–8 weeks in culture). It demands appropriate infrastructure and possibly the best laboratory personnel6 which can cause delays in efficient medical treatments. Therefore, the demand for novel, quick, and reliable diagnostic procedures has arisen.

Because the traditional bacteriological assessment of TB has numerous drawbacks, the NAAT (Nucleic Acid Amplification Test) has emerged as a viable substitute.7 NAAT systems have fast turnaround periods, uncomplicated testing and because of that treatment may begin on the same visit. Also, cutting the cost and frequency of follow-ups.8 For the detection of MTBC organisms, most NAAT tests look for mycobacterial insertion element.9 NAAT identifies MTB ribosomal RNA or DNA in sputum samples.10 NAAT has very high precision in smear-positive patients and a sensitivity range of 61-76% in smear-negative individuals.11 With the tremendous expansion of molecular methods, a broad range of NAAT to determine the presence of TB are now accessible. Polymerase chain reaction (PCR), real-time PCR, and loop-mediated isothermal amplification (LAMP) are examples of such techniques.

Rapid drug susceptibility tests (DST) and molecular diagnostic tests for MTBC identification would perhaps be an explanation for our prevailing TB diagnostic inadequacies. These diagnostics, unlike growth-based assays, depend on genetic information and are completed in hours instead of weeks. These assays have revolutionized the TB diagnostic paradigm enabling quick and precise diagnosis in TB-endemic locations wherever the culture-based assessment was formerly inaccessible. This review addresses the genetic approaches for detecting MTBC in clinical specimens as well as antibiotic resistance in mycobacterium and discusses the practical limitations of using these methods. Our search criteria included tuberculosis, drug resistance, early diagnosis, and molecular diagnostic approaches. We used PubMed, Scopus, and Google to find relevant articles. In this study, only peer-reviewed articles were considered.

Historically Significant Milestones in Tuberculosis Analysis
The growth of novel molecular approaches for the diagnosis of TB has accelerated in recent years. Nevertheless, that wasn’t always
the scenario before the PCR was introduced in 1985. The following are examples of the earliest commercially available PCR-based approaches for detecting MTBC.

**The *Mycobacterium tuberculosis* direct test (MTD)**

The FDA authorized the MTD test, an isothermal method, in December 1995, to detect MTBC rRNA using smear-positive respiratory samples. The MTD test uses transcription-mediated amplification (TMA) and the hybridization protection assay (HPA2) to qualitatively identify MTBC rRNA. Following CDC recommendations, the Grady Memorial Hospital microbiology laboratory introduced the amplified *Mycobacterium tuberculosis* Direct Test (MTD), a kind of NAAT from Hologic Gen-Probe (San Diego, CA) in 2000. According to the manufacturer, it was shown to have great sensitivity (96.9 %) and specificity (100%) when used for smear positive specimens. This suggests that it could be beneficial not only for the rapid detection of TB but also helpful in differentiating between TB and non-tuberculous mycobacteria (NTM) strains.

**Enhanced amplified *Mycobacterium tuberculosis* direct test (E-AMTDT)**

The FDA has authorized the E-AMTDT (Gen-Probe®, Inc., San Diego, CA) for the immediate evaluation of MTBC in respiratory samples obtained from individuals suspected of having TB. It is an RNA-based approach that depends on Kwoh’s isothermal transcription-mediated amplification mechanism. The significant aspects of this test are the speed and the reduced threat of cross-contamination. The foremost drawback of E-AMTDT is its failure to identify inhibitors because it lacks an internal amplification control (IAAC).

**COBAS Amplicor MTB Test**

This test was approved in 1996. The Roche Diagnostic Systems Cobas Amplicor PCR system for MTB detection (CA-PCR; Branchburg, NJ, USA) integrates specimen processing with controlled proliferation and diagnosis. The Cobas Amplicor test relies on biotinylated primers, a capture probe, and photometric labelling to quantify a 584-bp 5' segment of the 16S rRNA gene. This technique was thoroughly tested for diverse clinical samples and exhibited good sensitivity and specificity, principally for smear-positive samples.

**Ligase chain reaction (LCX) MTB Assay**

LCX MTB (Abbott Diagnostics Division, Abbott Park, III) intercepts MTBC in respiratory specimens using the ligase chain reaction. LCR depends on the combination of two particular oligonucleotide probes for adjoining sequences in the target DNA, a stretch of the MTB chromosome that specifies the protein antigen b, which is processed sequentially by polymerase and ligase. This gene sequence is unique to the MTBC. An enzyme conjugate trapped by the amplified ligase product enables the substrate to generate a fluorescence signal proportional to its concentration in the LCx analyzer. The cut-off determines whether the findings are positive or negative. During the last several years, multiple reports evaluated the sensitivity, specificity, and clinical usefulness of the LCx-MTB test for speedy identification of MTBC in respiratory and non-respiratory samples. They demonstrated that the LCx-MTB test is an effective TB diagnostic method. The Abbott LCx Probe System is quite costly due to the limited resources of the microbiological laboratory in underdeveloped countries, where TB has always been a major public health concern. Therefore, the LCx-MTB test can be housed in a single central laboratory that collaborates with local microbiological laboratories and clinical facilities. As a result, this test must be evaluated in situations that include specimen storage and transit from various locations. In 2002, this assay was pulled from the European market.

**BD ProbeTec-SDA (strand displacement amplification)**

Becton Dickinson (Sparks, MD) designed a semiautomated technique designated BD ProbeTec for the quick recognition of MTBC in respiratory specimens. The underlying principle used was a thermophilic variant of strand displacement amplification (SDA) that exponentially duplicated target nucleic acid sequences in measurable quantities. Becton Dickinson has successfully developed the latest system called BD ProbeTec ET, a novel device that connects SDA to a fluorescent energy transfer (thus, the “ET” designation) sensing mechanism. The BD ProbeTec ET system at the same time replicates and recognizes samples in a sealed homogeneous assay format, leading to increased productivity as well as a much speedier assessment.
<table>
<thead>
<tr>
<th>Test specifications</th>
<th>Technology used Organisms detected</th>
<th>Molecular target areas/genes</th>
<th>Test sensitivity</th>
<th>Test specificity</th>
<th>Turn-around time</th>
<th>Advantages</th>
<th>Limitations</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTD</td>
<td>Transcription-mediated amplification (TMA) and the hybridization protection assay (HPA2)</td>
<td><em>M. tuberculosis</em> complex</td>
<td>Ribosomal ribonucleic acid (rRNA)</td>
<td>96.9%</td>
<td>100%</td>
<td>2.5-3.5 hours</td>
<td>Quick diagnosis and detect rRNA from both cultivable and non-cultivable organisms</td>
<td>Reduced sensitivity was seen among acid-fast smear-negative specimens</td>
</tr>
<tr>
<td>E-AMTD</td>
<td>RNA-based Kwoh’s isothermal transcription-mediated amplification mechanism</td>
<td><em>M. tuberculosis</em> in smear-positive respiratory specimens</td>
<td>16S ribosomal transcripts</td>
<td>96%</td>
<td>95%</td>
<td>2.5 hours</td>
<td>Speed and the reduced threat of cross-contamination, high sensitivity and specificity</td>
<td>Failure to identify inhibitors as it lacks an internal amplification control (IAC).</td>
</tr>
<tr>
<td>COBAS Amplicor MTB Test</td>
<td>PCR amplification 16S rRNA gene</td>
<td><em>M. tuberculosis</em> in smear-positive respiratory specimens</td>
<td>584-bp segment of the 16S rRNA gene</td>
<td>82%</td>
<td>97%</td>
<td>5-6 hours</td>
<td>High sensitivity and specificity</td>
<td>Substantial rate of false-positive results, high cost and not widespread in TB laboratories.</td>
</tr>
<tr>
<td>GenoType line-probe assays (LPA)</td>
<td>PCR and reverse hybridization techniques</td>
<td>MTBC DNA and drug resistance</td>
<td>DNA strip</td>
<td>95%</td>
<td>100%</td>
<td>24-48 hours</td>
<td>High accuracy, detect Rif and INH resistance</td>
<td>More technically complex &amp; take longer to perform</td>
</tr>
<tr>
<td>Xpert MTB/RIF</td>
<td>Automated real-time polymerase chain reaction (PCR) test</td>
<td>MTB and rifampicin resistance</td>
<td>DNA Fragment</td>
<td>89%</td>
<td>99%</td>
<td>2 hours</td>
<td>Quick Result, Minimal technical training to run the test, quickly identify multidrug-resistant TB</td>
<td>Tested positive in patients previously treated for TB and more expensive</td>
</tr>
<tr>
<td>COBAS TaqMan MTB Test</td>
<td>Real-Time PCR assay</td>
<td>MTBC DNA</td>
<td>Amplifies part of the 16S rRNA gene with the use of a TaqMan probe</td>
<td>98%</td>
<td>100%</td>
<td>2.5 hours</td>
<td>Improved specificity and infections were reduced by 50%</td>
<td>Not sufficient in detecting <em>M. tuberculosis</em> in non-respiratory specimens</td>
</tr>
<tr>
<td>Xpert MTB/RIF Ultra BD MAX MDR-TB Assay</td>
<td>qPCR/melting temperature analysis (RIF resistance) Multiplex real-time PCR and targets specific fluorogenic probes</td>
<td>MTBC DNA</td>
<td>DNA Fragment</td>
<td>91.1%</td>
<td>94.5%</td>
<td>2 hours</td>
<td>Increased sensitivity</td>
<td>Sensitivity is inadequate in patients with paucibacillary disease Need stable source of electricity and laboratory technician training</td>
</tr>
<tr>
<td>Test specifications</td>
<td>Technology used</td>
<td>Organisms detected</td>
<td>Molecular target areas/genes</td>
<td>Test sensitivity</td>
<td>Test specificity</td>
<td>Turn-around time</td>
<td>Advantages</td>
<td>Limitations</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------</td>
<td>--------------------</td>
<td>-----------------------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>----------------</td>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>PURE-LAMP</td>
<td>Loop-mediated isothermal amplification (LAMP)</td>
<td>MTB diagnosis</td>
<td>DNA Fragment</td>
<td>98.2%</td>
<td>98%</td>
<td>1.5 hours</td>
<td>Economical, budget-friendly, and speedy technique for TB detection</td>
<td>Greater operator complexity, potential for cross-contamination and error in interpreting visual fluorescent readout</td>
</tr>
<tr>
<td>FluoroType® MTB</td>
<td>Real-time PCR</td>
<td>M. tuberculosis complex</td>
<td>DNA Fragment</td>
<td>88.1%</td>
<td>98.9%</td>
<td>3-4 hours</td>
<td>Less hands-on time, more-rapid result</td>
<td>Sensitivity and specificity of this new method for detecting RMP and INH resistance have not been investigated under routine conditions.</td>
</tr>
<tr>
<td>TrueNat MTB Micro RT-PCR</td>
<td>MTB diagnosis and rifampicin resistance</td>
<td>DNA Fragment</td>
<td>91%</td>
<td>100%</td>
<td>1 hour</td>
<td>The light weight, portable nature of the devices, good sensitivity and specificity and fits in resource-limited health care settings.</td>
<td>Cannot determine MDR-TB, which is of most significance in high burden countries.</td>
<td>76</td>
</tr>
<tr>
<td>Whole genome sequencing (WGS)</td>
<td>Automated genetic sequencing platforms</td>
<td>Multidrug resistant TB</td>
<td>DNA Fragment</td>
<td>85%</td>
<td>85%</td>
<td>1 hour</td>
<td>Quickly and comprehensively detect all possible drug resistance genes simultaneously</td>
<td>It relies on epidemiologically linked pairs, expensive and inaccessible to high burden low-income settings</td>
</tr>
</tbody>
</table>
In the era of antibiotic resistance, none of these techniques proved to be easy to use and cheap enough to be truly adequate for TB laboratory routine diagnosis.\textsuperscript{24}

**Innovations In Techniques for Molecular Diagnostics of Tuberculosis**

Molecular detection of MTBC has advanced significantly with the discovery of genetic variants related to resistance to the most widely used first- and second-line TB drugs. These techniques employ an extensive range of targets, including genus or species-specific DNA or RNA segments.

**GenoType line-probe assays (LPA)**

Molecular tests for screening gene alterations that indicate drug resistance are considered ideal for prompt diagnosis, particularly because assays can be used directly on diagnostic samples.\textsuperscript{25} LPA have demonstrated considerable potential among molecular assays.\textsuperscript{26} LPA is a class of newer DNA strip-based assays that employ NAAT like PCR and reverse hybridization techniques to detect drug resistance mutations rapidly. Currently, there are two accessible LPAs, that is, the INNO-LiPA® Rif TB assay and the GenoType® MTBDRplus assay. Hain Lifescience, a German company, invented Genotype MTBDRplus. INNO-LiPA Rif. TB was developed by Innogenetics, a Belgian company.

Innogenetics introduced the INNOLiPA Rif.TB assay in 1995, the first commercially accessible and widely used line probe assay generally accessible for detecting MTBC DNA and drug resistance mutations.\textsuperscript{27} LiPA managed to give results within one to two days. It was approved by the WHO in 2008. A meta-analysis by the WHO looked at the performance of the LiPA assay. It found that it had a sensitivity higher than 95% and a specificity of 100% for the identification of MTBC isolates.\textsuperscript{26} When the LiPA was used directly on clinical samples, it had 100% specificity and sensitivity that varied from 80% to 100%.\textsuperscript{26}

Hain Lifescience introduced the GenoType MTBDR, a qualitative in-vitro test in 2004. The Genotype MTBDR assay targets rpoB RPDR and katG codon 315 which are possibly the most common. The research compared to phenotypic DST, MTBDR has a sensitivity and specificity of 99% and 100% for rifampicin resistance, respectively, and 88.4% and 100% for isoniazid resistance, respectively.\textsuperscript{28}

The limited sensitivity of the test to detect isoniazid resistance was its main drawback in achieving a significant improvement in the number of isoniazid-resistant strains. In 2007, Hain made a second-generation test called Genotype MTBDRplus VER 1.0 (MTBDRplus). This is for all genes that the previous version targeted, but adds codons 505 to 510 to the RRDR of the rpoB gene. In 2008, the WHO validated MTBDRplus VER 1.0.\textsuperscript{26} The genotype MTBDRplus VER 2.0 was approved by WHO in 2012 as a quantifiable in-vitro methodology for the identification of the MTBC and instantaneous sensing of mutations in the rpoB and katG genes. This test takes around 6 hours to complete.\textsuperscript{29} Investigations\textsuperscript{30-31} indicate that the analytical effectiveness of Genotype MTBDRplus Version 2.0 LPA for the identification of MDR-TB in direct smear-positive sputum samples was remarkably accurate and explicit. Furthermore, the reliability of the assay to detect MDR-TB in direct smear-negative sputum samples must be strengthened.\textsuperscript{32} All the chemicals essential for amplification in this assay are included in the amplification mix and they are no longer required to be administered separately. Processing time is comparable. MTBDRplus exhibited a high rate of recognition of resistance to rifampicin in both MTB strains and clinical specimens.

The GenoType MTBDRsl test is the third in the sequence of LPA assays. The test uses the same technology as its predecessor but recognizes mutations synonymous with second-line drug resistance. Specifically, to improve the capability to identify low-level kanamycin tolerance, MTBDRsl VER 2.0 was developed in 2015 to enhance the efficiency of the GenoType MTBDRsl assay. The GenoType MTBDRsl 2.0-line probe assay\textsuperscript{33} was devised as a means to identify MTB, as well as to simultaneously recognize the presence of resistance-inducing mutations in fluoroquinolones (gyrA and gyrB genes) and second-line intravenous medications (SLID) (rrs and eis genes).\textsuperscript{34} The particular section for the screening of resistance to ethambutol (embB codon 306) that was included in MTBDRsl v1 has been deleted from MTBDRsl v2.0. WHO advised using the GenoType MTBDRsl 2.0 assay rather than phenotypic DST.\textsuperscript{35}
Gene Xpert TB Assays/ Xpert MTB/RIF

The Xpert MTB/RIF assay is a novel technique that redefines TB management and facilitates rapid detection of TB disease. Xpert MTB/RIF (Cepheid Inc.) is a GeneXpert-based automated real-time PCR assay (Fig. 1). The time it takes to identify MTB and rifampicin resistance after starting the analysis is just around two hours with little technical effort. Both the WHO and the US Food and Drug Administration (FDA) have given their approval for its use. This technique may be employed on clinical specimens including pure sputum samples as well as samples generated after disinfection and concentration of sputum. When compared to previous approaches, many studies have shown that Xpert MTB/RIF is a more precise approach for quick TB screening. Upon a negative response to AFB smear microscopy, Xpert MTB/RIF can be utilized as a first as well as a supplementary assay to confirm the diagnosis and has minimized the current estimate for therapy for AFB smear-negative TB from 56 to 5 days. Xpert MTB/RIF, the leading primary diagnostic test for TB and antibiotic resistance, is an in-vitro screening test introduced in 2009 to be used within the fully automated GeneXpert platform. In 2013, FDA approved the Xpert MTB/RIF. A systematic assessment of the specificity and accuracy of the Xpert MTB/RIF for TB screening predicted pooled diagnostic accuracy of 89% - 99% correspondingly. In culture-positive patients with negative smear, the pooled sensitivity was 67%. Xpert MTB/RIF assay’s important clinical significance is that it is fully automated, safe, and quickly recognizes MTB DNA and genetic alterations that cause rifampicin resistance as a biomarker for MDR-TB. Several investigations revealed significant limits in the performance of the Xpert MTB/RIF test. Among them is the inability to identify rifampicin resistance-related alterations in mixtures and the inability to identify the C533G rpoB mutation that is correlated with rifampicin susceptibility. A revised variant of the test, the Xpert MTB/RIF Ultra, has been created to increase the sensitivity and accuracy of the assay.

Loop-mediated isothermal amplification-based MTB detection assay (LAMP)

Notomi et al., from Eiken Chemical Company- Japan, designed the LAMP test. LAMP has been effectively used as a diagnostic method in clinical research. LAMP is an isothermal nucleic acid multiplication technology that utilizes a constant temperature to amplify nucleic acids without the necessity of a thermal cycler. Under isothermal circumstances, this technique

Fig. 1. Xpert MTB/RIF Assay Overview.
Table 2. Characteristics of molecular assays for detection of MTB and drug-resistance not approved by WHO and/or FDA

<table>
<thead>
<tr>
<th>Test specifications</th>
<th>Technology used</th>
<th>Organisms detected</th>
<th>Molecular target areas/genes</th>
<th>Test sensitivity</th>
<th>Test specificity</th>
<th>Turn-around time</th>
<th>Advantages</th>
<th>Limitations</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCX MTB Assay</td>
<td>Ligase-based gene amplification</td>
<td><em>M. tuberculosis</em></td>
<td>Target DNA to be amplified was the gene encoding the 38-kDa protein</td>
<td>88%</td>
<td>98%</td>
<td>5-6 hours</td>
<td>Automated microparticle enzyme immunoassay detection of the amplified product with the LCx analyzer</td>
<td>LCx MTB system cannot detect the presence of inhibitors in the reaction</td>
<td>83</td>
</tr>
<tr>
<td>BD ProbeTec SDA</td>
<td>Strand displacement amplification of CT/GC Amplified DNA</td>
<td><em>M. tuberculosis</em></td>
<td>Target sequences of IS6110 and 16S rRNA gene are co-amplified</td>
<td>93%</td>
<td>92%</td>
<td>3.5-4 hours</td>
<td>Relatively high output and sensitivity</td>
<td>Low positive predictive values</td>
<td>84</td>
</tr>
<tr>
<td>LAMP</td>
<td>Isothermal nucleic acid amplification technique</td>
<td><em>M. tuberculosis</em> infection</td>
<td>DNA sequences</td>
<td>92%</td>
<td>95.6%</td>
<td>Less than one hour</td>
<td>Relatively high-throughput, does not require sophisticated instrumentation</td>
<td>Greater operator complexity, potential for cross-contamination and error in interpreting visual fluorescent readout</td>
<td>51, 52</td>
</tr>
</tbody>
</table>
multiplies relatively few copies of DNA sequences with excellent accuracy, reliability, and efficiency employing a combination of four specially engineered primers and a DNA polymerase with strand displacement capability. LAMP was proposed by WHO in August 2016 as a viable substitute for smear microscopy for evaluating pulmonary TB in individuals. For smear-positive specimens, TB-LAMP had a stronger specificity of 92.1%–100% compared to smear-negative samples 52.1% – 90.3%. A recent investigation demonstrates that LAMP showed a high sensitivity (95.6%) in extra-pulmonary TB samples when contrasted to traditional methods. The efficacy of TB-LAMP assessment using extrapolmonary samples is currently being investigated. The TB-LAMP can turn out to be the ultimate molecular test for TB detection; however, excessive heat, moisture, insufficient reagent amount, and cross-contamination amongst specimens have been highlighted as key contributors to false-positive responses.

**Promising Developments in TB Molecular Diagnostics**

Based on the current WHO flow path for the TB molecular assessment, innovative advancements are currently in different phases of progression with the vast majority still in the initial phases of development while others are present in the WHO appraisal and are portrayed below.

**COBAS TaqMan MTB (CTM Test)**

A new MTB test, the Cobas TaqMan MTB test, has been introduced by Roche Diagnostics (Rotkreuz, Switzerland), which has superseded the Cobas Amplicor MTB test. This technique is based on real-time PCR that uses a TaqMan probe to intensify the 16S rRNA gene segment to recognize MTBC DNA in clinical samples. According to the manufacturer’s recommendations, CTM should only be used on respiratory samples. However, several investigations have been conducted to assess the efficacy of the CTM test in non-respiratory specimens. Studies indicate that the Cobas test is more accurate regarding smear-positive samples than it is regarding smear-negative samples that could be associated with the purification and concentration stages. The assay’s sensitivity varied from 96.9% - 98% in the smear-positive sample as well as 34.9% - 79.5% in the smear-negative samples. Additionally, the specificity ranges from 78.1%-100% in smear-positive samples as well as from 98.7%-99% in smear-negative samples. However, these findings differ from one research to another. According to some studies, this variation is attributable due to the AFB smear condition, distinctive specimen categories, and the prevalence of TB. Thus, the Cobas TaqMan MTB test findings should indeed be thoroughly evaluated in association with the clinical evidence.

**Xpert MTB/RIF Ultra**

The Xpert MTB/RIF Ultra has a larger reaction area and also has two genetic markers, IS6110 and IS1081 in it. All of this works together to lower the detection limit to 15.6 CFU/ml. Also, it increases the sensitivity up to ten times.

**GeneXpert Omni and Xpert XDR**

Cepheid intends to introduce the GeneXpert Omni, a significant technical development for evaluating TB and rifampicin resistance that will use the same cartridges as the present in GeneXpert equipment. The GeneXpert Omni is a single-cartridge portable diagnostics machine that cost less than other GeneXpert tests and can run for four hours on a single charge. Due to the aforementioned qualities, it is extremely helpful, particularly in rural areas with inadequate infrastructure, for quick identification of TB. Omni was scheduled to be released in developing markets at the end of 2018; however, the WHO has not yet marketed or reviewed it. The Xpert® MTB/XDR cartridge enables clinicians to quickly prescribe treatment regimens for MDR-TB and XDR-TB.

**BD MAX MDR-TB Assay**

It was developed by Becton and Dickinson to detect MTBC DNA and mutations that give resistance to rifampicin and isoniazid. It is a fully automated machine that utilizes multiplex real-time PCR and targets specific fluorogenic probes. Target the mutation in the rpoB and katG genes and in the inhA promoter region. This assay was specifically designed for analyzing raw or concentrated sputum. The BD MAX MDRTB
test was introduced in June 2018. The research demonstrated good sensitivity and specificity.

**PURE-LAMP**

The PURE-LAMP is a quantitative TB diagnostic assay designed by Eiken Chemical Company-Japan between 2007-2010. This test could be performed in approximately 90 minutes and consists of the following steps, i.e., sample processing, LAMP amplification, and visual evaluation of fluorescent illumination from the reaction tube using ultraviolet rays. Several studies have shown that PURE-LAMP has very significant diagnostic accuracy, making it an economical, budget-friendly, and speedy technique for TB detection. According to research, the sensitivity of the test is 55.6% in patients with a negative smear and 98.2% in patients with a positive smear. According to N’guessan et al., the PURE-LAMP test has a greater sensitivity than that of smear microscopy. However, the specificity of the smear microscopy was greater than that of PURE-LAMP. Thus, PURE-LAMP should be used in conjunction with many other analytical procedures to support the presence of TB, particularly in false-negative samples.

**FluoroType® MTB**

FluoroType® MTB analysis (Hain Lifescience, Nehren, Germany) detects MTBC in pulmonary and non-pulmonary clinical isolates using real-time PCR. The HyBeacon fluorescence technique has been used in the FluoroType® MTB assessment. The amplifications were performed using Hain Lifescience FluoroCycler equipment, and the analysis was performed with a melt response curve with single-stranded DNA fragments marked with fluorescent dyes that are complementary to the amplified DNA. The technique yields responses in 3-4 hours for numerous samples. In contrast to culture, Hofmann-Thiel and Hoffmann discovered that the FluoroType® MTB test exhibited a sensitivity of 88.1% and a specificity of 98.9%. There are two versions of FluoroType® MTB. FluoroType MTB VER 1.0 is used for decontaminated pulmonary and extrapulmonary samples, and FluoroType® MTB VER 2.0 is used for decontaminated pulmonary samples.

**The TrueNat MTB**

It is a novel approach that can identify resistance to MTB and rifampicin in one hour. The TrueNat model was implemented by the Indian company MolBio Diagnostics Pvt Ltd, Goa. The Bigtec Labs in India financed its development. As the complete system is battery-powered and mobile, it may be employed at the most elementary tiers of the healthcare system. It functions by efficiently screening for TB bacteria using the PCR assay. The isolated DNA is then put onto a TrueNat MTB (or MTB plus) chip that has already been preloaded with stabilized reagents.
The Truelab UnoDx real-time PCR analyzer, a portable battery-powered instrument, is then used for rapid amplification and analysis. If the TrueNat MTB chip (or MTB plus) produces a positive result (depending on the diagnostic algorithm used), the user can then insert another aliquot of extracted DNA into an additional TrueNat MTB-RIF Dx chip to identify the presence of specific mutations linked to resistance to rifampicin. The system searches for DNA that is unique to the TB bacterium. If it is detected, the machine will utilize PCR to amplify specific segments of DNA, which may subsequently be employed in a variety of laboratory processes. If resistance to rifampicin is discovered, a second RT-PCR was performed. The TrueNat MTB test demonstrated 91% sensitivity and 100% specificity against a composite reference standard in a pilot study conducted in India, including 99% specificity for smear-positive, culture-positive samples and 76% sensitivity for smear-negative, culture-positive samples.

Whole-genome sequencing (WGS)

WGS techniques, which use automated genetic sequencing platforms, have been suggested as the most effective molecular diagnostic test for MTB and the identification of all genetic factors for resistance. Microbial biotech has made it possible to look at the genetic markers of organisms that could affect treatment and infection prediction. WGS has now become an economical & easy approach to identify microevolutions within MTB lineages when they are transferred across hosts. The WGS workflow is depicted in Fig. 2, showing sample collection to clinical diagnostic evaluation. First-generation and second-generation sequencers (commonly known as the next-generation sequencer) are available. Despite its slowness, the first-generation sequencer has a maximum speed and a low price. The second generation seems to have lesser productivity and higher expense and can sequence numerous genomes in much less than a day.

CONCLUSIONS

The future of molecular diagnostic analysis for active TB of the lungs appears promising and it should be developed in a way that improves public health. Molecular methodologies certainly had a significant influence on patient care and have been one of the most significant methods in recent years to validate the presence of MTB in the laboratory. Even while this approach is useful in mycobacteriology labs, it isn’t the only way to address all questions. We must be aware of the limits of these methods when they are used. These incorporate technical glitches such as suppression of amplification, cross-contamination, and significantly lower accessibility; the need for expensive reagents, and input costs; constrained multiplexing potential; significantly longer response times, particularly for DNA retrieval, and the need for technical knowledge and specific amenities. To determine whether a particular diagnostic molecular technology is suitable for a specific clinical environment, factors such as testing capacity, diagnostic yield, and practicality of performing the test in the laboratory must be taken into account.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS’ CONTRIBUTION

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

None.

ETHICS STATEMENTS

Not Applicable.

DATA AVAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

REFERENCES

13. Centers for Disease Control and Prevention. Update:
15. Kwoh DY, Davis GR, Whitfield KM, Chappelle HL,
11. Centers for Disease Control and Prevention. Updated
5. Dezemon Z, Muvunyi CM, Jacob O. Staining techniques


